🇺🇸 fenofibrate + rosuvastatin in United States

23 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 23

Most-reported reactions

1. Blood Cholesterol Increased — 4 reports (17.39%)
2. Blood Triglycerides Increased — 3 reports (13.04%)
3. Asthenia — 2 reports (8.7%)
4. Blood Glucose Increased — 2 reports (8.7%)
5. Chest Pain — 2 reports (8.7%)
6. Dyspepsia — 2 reports (8.7%)
7. Gamma-Glutamyltransferase Increased — 2 reports (8.7%)
8. Malignant Neoplasm Progression — 2 reports (8.7%)
9. Oedema Peripheral — 2 reports (8.7%)
10. Vomiting — 2 reports (8.7%)

Source database →

Frequently asked questions

Is fenofibrate + rosuvastatin approved in United States?

fenofibrate + rosuvastatin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for fenofibrate + rosuvastatin in United States?

University of Campania Luigi Vanvitelli is the originator. The local marketing authorisation holder may differ — check the official source linked above.